Kura Oncology (KURA) Current Deferred Revenue (2024 - 2026)
Kura Oncology (KURA) posted quarterly Current Deferred Revenue of $47.7 million for Q1 2026, up 16.79% year-over-year from $40.8 million in Q1 2025, and down 2.61% quarter-over-quarter from $49.0 million in Q4 2025.
Kura Oncology (KURA) Current Deferred Revenue (2024 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Current Deferred Revenue for 3 consecutive years, with $47.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 16.79% year-over-year to $47.7 million; the TTM figure through Mar 2026 stood at $47.7 million (up 16.79% YoY), while the FY2025 annual figure was $49.0 million, up 101.82% from the prior year.
- Current Deferred Revenue declined to $47.7 million in Q1 2026 per KURA's latest filing, from $49.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $49.4 million in Q2 2025 and bottomed at $24.3 million in Q4 2024.
- Historically, Current Deferred Revenue has averaged $43.3 million across 3 years, with a median of $48.2 million in 2025.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue surged 101.82% — and 2026, when it rose 16.79%.
- Kura Oncology's Current Deferred Revenue stood at $24.3 million in 2024, then surged by 101.82% to $49.0 million in 2025, then fell by 2.61% to $47.7 million in 2026.
- Business Quant data shows KURA's Current Deferred Revenue at $47.7 million in Q1 2026, $49.0 million in Q4 2025, and $48.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.48 Mn |
| Mar 31, 2026 | 47.70 Mn |
| Dec 31, 2025 | 48.98 Mn |
| Sep 30, 2025 | 48.75 Mn |
| Jun 30, 2025 | 49.44 Mn |
| Mar 31, 2025 | 40.85 Mn |
| Dec 31, 2024 | 24.27 Mn |